Anales del Sistema Sanitario de NavarraFundamento. La infección por el virus respiratorio sincitial (VRS) es la principal causa de hospitalización en lactantes. En 2022 se autorizó el nirsevimab en la Unión Europea para prevenir la enfermedad respiratoria grave por VRS durante el primer año ...
Noelia Vera-Punzano +11 more
doaj +3 more sources
Did Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024–2025) [PDF]
VirusesNirsevimab is a long-acting monoclonal antibody designed to prevent infections due to respiratory syncytial virus (RSV). Here we report on a retrospective, multicenter study encompassing a total of 19 Italian neonatal and pediatric centers evaluating the
Paolo Manzoni +32 more
doaj +2 more sources
Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria [PDF]
Frontiers in Public HealthBackgroundSince summer 2024, passive immunization with nirsevimab (Beyfortus®) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection.
Michaela Höck +14 more
doaj +2 more sources
Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023–2024 Season in Andalusia, Spain (NIRSEGRAND) [PDF]
VaccinesBackground: Nirsevimab was indicated in a population level for all infants < 6 months during the 2023–2024 season in Andalusia (southern Spain). Our aim was to analyse the effect of nirsevimab in the reduction in complications in infants hospitalised for
David Moreno-Pérez +13 more
doaj +2 more sources
Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross-Sectional Study. [PDF]
Pediatr PulmonolABSTRACT Introduction New RSV prevention products show strong potential, but their success depends on wide acceptance and use. We assessed Ontario pediatricians' knowledge and attitudes about these products before their introduction to highlight opportunities and barriers.
Rose A +4 more
europepmc +2 more sources
Two-season effectiveness of a single nirsevimab dose against RSV hospitalisation in healthy term-born infants: a population-based case–control study, Spain, October 2023 to March 2025 [PDF]
EurosurveillanceBACKGROUND In autumn 2023, Spain recommended nirsevimab to all infants born after 1 April 2023, as catch-up or at-birth immunisation. AIM We estimated effectiveness of a single nirsevimab dose against respiratory syncytial virus (RSV) hospitalisations ...
the Nirsevimab Effectiveness Study Collaborators
doaj +2 more sources
Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab. [PDF]
Pediatr Infect Dis JBackground: Nirsevimab is approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Although nucleic acid detection by polymerase chain reaction is primarily utilized for the clinical diagnosis of RSV, antigen detection is still routinely used and ...
Sincero SR +7 more
europepmc +3 more sources
Potential Effects on Elderly People From Nirsevimab Use in Infants
Open Respiratory ArchivesNirsevimab therapy has the potential to revolutionize infant respiratory syncytial virus (RSV) prophylaxis. But other populations suffering RSV, such the elderly or those over 60, may also be protected by using this novel antibody in the infant group. It
Ivan Sanz-Muñoz, JOSÉ Maria Eirós
exaly +3 more sources
Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants. [PDF]
Pediatr PulmonolABSTRACT Introduction Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infants. Since 2023, France has implemented two preventive strategies aimed at reducing RSV burden: long‐acting monoclonal antibody nirsevimab and RSV vaccine for pregnant women, the latter becoming available from September 2024.
Tarizzo M +7 more
europepmc +2 more sources
VaccinesBackground: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants, particularly those with risk factors such as prematurity or chronic diseases.
Susanna Esposito +10 more
doaj +2 more sources